Mylan to acquire Meda in $9.9 billion deal
Mylan N.V. plans to acquire Sweden-based pharmaceuticals manufacturer Meda AB in a deal valued at $9.9 billion, including debt. Mylan said late Wednesday that the offer to Meda includes cash and Mylan shares, with the equity portion valued at $7.2 billion.